Apollo Hospitals Enterprise quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	7,044	5,842	+20.6%
EBITDA	1,092	852	+28.2%
EBITDA margin	15.5%	14.6%	+0.9 pts
Profit before tax	785	569	+38.0%
Net profit	610	441	+38.4%
EPS	₹40.39	₹30.10	+34.2%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	7,044	6,606	6,477	6,304	5,842	5,592	5,527	5,589	5,086	4,944	4,851	4,847	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	48.8	43.9	52.8	54.7	40.2	61.1	63.8	38.2	37.2	28.1	27.8	22.2
	7,092	6,649	6,530	6,358	5,882	5,653	5,591	5,628	5,123	4,972	4,878	4,869
	829	777	745	779	740	694	626	744	690	638	603	633
	2,768	2,613	2,663	2,465	2,316	2,244	2,292	2,110	1,911	1,914	1,944	1,841
	0.3	11.5	−25.3	0.2	−8.0	−9.4	−16.9	3.0	22.2	−5.9	−13.8	−14.5
	796	772	749	767	713	725	686	700	658	645	613	644
	120	119	113	110	108	115	110	118	116	119	113	111
	235	224	219	218	215	211	185	185	177	190	167	163
	1,559	1,421	1,381	1,352	1,230	1,169	1,178	1,216	1,129	1,113	1,091	1,117
	6,307	5,938	5,844	5,690	5,313	5,148	5,060	5,076	4,704	4,612	4,517	4,494
	1,092	1,011	965	941	852	770	762	816	675	641	614	628
	857	787	746	723	637	559	577	631	498	451	447	464
Profit
	785	711	686	668	569	505	531	552	419	360	362	375
	0.0	0.0	−19.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9
	785	711	667	668	569	505	531	552	419	360	362	377
	210	196	147	162	125	119	135	160	113	88.7	113	133
	−21.9	−25.8	18.7	19.2	16.9	−18.0	22.3	1.9	1.5	21.1	−4.3	−2.3
	188	170	166	181	142	101	157	162	115	110	109	130
	13.4	10.1	14.9	6.3	13.6	10.5	5.3	5.7	11.5	8.6	1.4	2.1
	610	551	516	494	441	415	379	396	316	258	254	249
	597	541	501	488	427	404	374	390	304	250	253	247
	3.9	−4.1	−0.2	56.8	5.9	−3.0	−2.9	−5.5	5.2	−0.2	0.8	−9.3
	614	547	516	551	447	412	377	390	321	258	255	240
	581	529	502	477	433	390	372	379	305	254	245	233
	29.7	22.0	14.0	16.8	8.2	24.9	7.1	16.9	10.3	4.6	9.1	15.9
Per share
	₹40.39	₹36.82	₹34.94	₹33.19	₹30.10	₹27.10	₹25.89	₹26.34	₹21.23	₹17.65	₹17.06	₹16.20
	₹40.37	₹36.76	₹34.94	₹33.19	₹30.10	₹27.10	₹25.89	₹26.34	₹21.23	₹17.65	₹17.06	₹16.20
Other comprehensive income — detail
	3.9	−4.1	−0.2	56.8	5.9	−3.0	—	—	—	—	—	—
	4.0	−8.6	−0.9	65.3	6.1	−3.8	−3.4	−6.6	5.2	−0.3	1.2	−13.0
	0.2	−3.1	−0.3	9.6	0.2	−0.9	—	—	—	—	—	—
	—	—	—	—	—	—	0.1	−0.9	0.0	−0.1	0.3	−3.3
	0.1	1.4	0.4	1.1	0.0	−0.1	0.6	0.2	—	0.0	−0.1	0.4
	585	525	502	534	439	387	370	374	310	253	246	224
	29.6	22.6	13.9	17.1	8.1	24.4	7.0	16.2	10.3	4.8	8.8	15.8
Per share — as-filed variants
	₹40.39	₹36.82	₹34.94	₹33.19	₹30.10	₹27.10	₹25.89	₹26.34	₹21.23	₹17.65	₹17.06	₹16.20
	₹40.37	₹36.76	₹34.94	₹33.19	₹30.10	₹27.10	₹25.89	₹26.34	₹21.23	₹17.65	₹17.06	₹16.20
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	3,446	3,204	3,095	3,060	2,795	2,664	2,626	2,732	2,463	2,398	2,318	2,388
	48.9%	48.5%	47.8%	48.5%	47.8%	47.6%	47.5%	48.9%	48.4%	48.5%	47.8%	49.3%
Adjusted (ex-exceptional items) — derived
	785	711	686	668	569	505	531	552	419	360	362	375
	0.0	0.0	−19.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9
	610	551	531	494	441	415	379	396	316	258	254	248
	₹40.39	₹36.82	₹35.92	₹33.19	₹30.10	₹27.10	₹25.89	₹26.34	₹21.23	₹17.65	₹17.06	₹16.12

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APOLLOHOSP₹8,137.00

Apollo Hospitals Enterprise Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersFORTIS MAXHEALTH MEDANTA SUNPHARMA CIPLA DRREDDY DIVISLAB TORNTPHARMMcap ₹1.17L Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	4,846.9	4,850.6	4,943.9	5,085.6	5,589.3	5,526.9	5,592.2	5,842.1	6,303.5	6,477.4	6,605.5	7,043.5
Other Income	22.2	27.8	28.1	37.2	38.2	63.8	61.1	40.2	54.7	52.8	43.9	48.8
Total Income	4,869.1	4,878.4	4,972.0	5,122.8	5,627.5	5,590.7	5,653.3	5,882.3	6,358.2	6,530.2	6,649.4	7,092.3
Expenses
+ Cost of Materials Consumed	632.5	603.3	637.5	690.1	744.3	625.6	694.4	740.1	778.7	744.6	777.4	829.0
+ Purchases of Stock-in-Trade	1,840.5	1,943.6	1,914.1	1,910.7	2,110.4	2,292.0	2,243.6	2,315.5	2,464.7	2,663.1	2,613.1	2,767.8
+ Changes in Inventories	-14.5	-13.8	-5.9	22.2	3.0	-16.9	-9.4	-8.0	0.2	-25.3	11.5	0.3
+ Employee Benefit Expense	644.1	612.9	644.9	658.1	700.1	686.4	724.6	712.6	766.7	749.0	772.0	795.8
+ Finance Costs	111.3	112.6	119.3	116.4	117.5	109.8	114.8	108.3	109.6	112.6	119.1	120.4
+ Depreciation & Amortisation	163.4	167.0	189.7	177.4	184.5	184.6	211.0	214.7	217.8	219.2	224.4	235.1
+ Other Expenses	1,116.8	1,090.9	1,112.8	1,129.4	1,216.0	1,178.3	1,169.3	1,230.0	1,352.1	1,380.7	1,420.5	1,558.5
Total Expenses	4,494.1	4,516.5	4,612.4	4,704.3	5,075.8	5,059.8	5,148.3	5,313.2	5,689.8	5,843.9	5,938.0	6,306.9
EBITDA	627.5	613.7	640.5	675.1	815.5	761.5	769.7	851.9	941.1	965.3	1,011.0	1,092.1
EBIT	464.1	446.7	450.8	497.7	631.0	576.9	558.7	637.2	723.3	746.1	786.6	857.0
Profit
PBT before Exceptional Items	375.0	361.9	359.6	418.5	551.7	530.9	505.0	569.1	668.4	686.3	711.4	785.4
+ Exceptional Items	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-19.2	0.0	0.0
Pretax Income	376.9	361.9	359.6	418.5	551.7	530.9	505.0	569.1	668.4	667.1	711.4	785.4
+ Current Tax	132.5	113.2	88.7	113.0	159.8	134.5	119.0	124.8	161.5	147.0	196.0	210.3
+ Deferred Tax	-2.3	-4.3	21.1	1.5	1.9	22.3	-18.0	16.9	19.2	18.7	-25.8	-21.9
Tax Expense	130.2	108.9	109.8	114.5	161.7	156.8	101.0	141.7	180.7	165.7	170.2	188.4
+ Share of Associates & JVs	2.1	1.4	8.6	11.5	5.7	5.3	10.5	13.6	6.3	14.9	10.1	13.4
Net Income	248.8	254.4	258.4	315.5	395.7	379.4	414.5	441.0	494.0	516.3	551.3	610.4
+ Net Income — Continuing Ops	246.7	253.0	249.8	304.0	390.0	374.1	404.0	427.4	487.7	501.4	541.2	597.0
+ Other Comprehensive Income	-9.3	0.8	-0.2	5.2	-5.5	-2.9	-3.0	5.9	56.8	-0.2	-4.1	3.9
Total Comprehensive Income	239.5	255.2	258.2	320.7	390.2	376.5	411.5	446.9	550.8	516.1	547.2	614.3
Net Income to Common	232.9	245.3	253.8	305.2	378.8	372.3	389.6	432.8	477.2	502.3	529.3	580.7
Minority Interest	15.9	9.1	4.6	10.3	16.9	7.1	24.9	8.2	16.8	14.0	22.0	29.7
Per Share
Basic EPS	16.20	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	34.94	36.82	40.39
Diluted EPS	16.20	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	34.94	36.76	40.37
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-3.0	5.9	56.8	-0.2	-4.1	3.9
+ Items NOT to be Reclassified to P&L	-13.0	1.2	-0.3	5.2	-6.6	-3.4	-3.8	6.1	65.3	-0.9	-8.6	4.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.9	0.2	9.6	-0.3	-3.1	0.2
+ Tax on Items NOT to be Reclassified — alt tag	-3.3	0.3	-0.1	0.0	-0.9	0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	0.4	-0.1	0.0	—	0.2	0.6	-0.1	0.0	1.1	0.4	1.4	0.1
Comprehensive Income — Owners of Parent	223.7	246.4	253.4	310.4	374.0	369.5	387.1	438.8	533.7	502.2	524.6	584.7
Comprehensive Income — Non-controlling Interests	15.8	8.8	4.8	10.3	16.2	7.0	24.4	8.1	17.1	13.9	22.6	29.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	16.20	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	34.94	36.82	40.39
Diluted EPS — Continuing Operations	16.20	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	34.94	36.76	40.37
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,388.4	2,317.5	2,398.2	2,462.6	2,731.6	2,626.2	2,663.6	2,794.5	3,059.9	3,095.0	3,203.5	3,446.4
Gross Margin %	49.28	47.78	48.51	48.42	48.87	47.52	47.63	47.83	48.54	47.78	48.50	48.93
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	375.0	361.9	359.6	418.5	551.7	530.9	505.0	569.1	668.4	686.3	711.4	785.4
− Exceptional Items (reconciliation)	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-19.2	0.0	0.0
Net Income Adj (tax-effected)	247.6	254.4	258.4	315.5	395.7	379.4	414.5	441.0	494.0	530.7	551.3	610.4
EPS Adj	16.12	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	35.92	36.82	40.39
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00	5.00	10.00	5.00	10.00	5.00	5.00	5.00
Paid Up Equity Capital	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Apollo Hospitals Enterprise Q2 FY27 results date

Apollo Hospitals Enterprise (NSE: APOLLOHOSP) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 12 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹581 crore, up 34.2% from ₹433 crore in Q1 FY26 and up 9.7% from ₹529 crore in Q4 FY26. Revenue from operations was ₹7,044 crore, up 20.6% year on year and up 6.6% from the previous quarter.

Board-meeting notice filed: 12 October 2026
Q2 FY26 results (a year earlier): 6 November 2025
Q1 FY27 results (the latest): 12 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 12 Oct
Q1 FY27 net profit: ₹581 Cr+34.2% vs Q1 FY26+9.7% vs Q4 FY26
Q1 FY27 revenue: ₹7,044 Cr+20.6% vs Q1 FY26+6.6% vs Q4 FY26
Q1 FY27 operating margin: 12.2%+1.3 pts vs Q1 FY26+0.3 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹477 CrRevenue ₹6,304 Cr
Q1 FY27 EPS (basic): ₹40.39

Questions

When will Apollo Hospitals Enterprise announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 12 October 2026). Last year it reported Q2 FY26 on 6 November 2025.

What will Apollo Hospitals Enterprise's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹477 crore and revenue from operations ₹6,304 crore. The latest quarter, Q1 FY27, had a net profit of ₹581 crore and revenue of ₹7,044 crore.

What was Apollo Hospitals Enterprise's revenue in FY26?

Revenue from operations was ₹25,229 crore in FY26 (April 2025–March 2026), up 15.8% from ₹21,794 crore in FY25. It was ₹19,059 crore in FY24 and ₹16,612 crore in FY23: up 51.9% over three years, 14.9% a year on average.

What were Apollo Hospitals Enterprise's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹581 crore, up 34.2% from ₹433 crore in Q1 FY26 and up 9.7% from ₹529 crore in Q4 FY26. Revenue from operations was ₹7,044 crore, up 20.6% year on year and up 6.6% from the previous quarter.

How has Apollo Hospitals Enterprise's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹477 crore in Q2 FY26, ₹502 crore in Q3 FY26, ₹529 crore in Q4 FY26 and ₹581 crore in Q1 FY27. That is ₹2,090 crore over the four quarters, up 32.8% from ₹1,574 crore in the four quarters before. Revenue from operations: ₹6,304 crore, ₹6,477 crore, ₹6,606 crore and ₹7,044 crore.

What was Apollo Hospitals Enterprise's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹1,942 crore in FY26 (April 2025–March 2026), up 34.3% from ₹1,446 crore in FY25. It was ₹899 crore in FY24 and ₹819 crore in FY23: up 137.1% over three years, 33.3% a year on average.

Where do these Apollo Hospitals Enterprise figures come from?

From Apollo Hospitals Enterprise's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.